1. Home
  2. IHS vs IDYA Comparison

IHS vs IDYA Comparison

Compare IHS & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IHS Holding Limited

IHS

IHS Holding Limited

HOLD

Current Price

$8.21

Market Cap

2.5B

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$32.13

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHS
IDYA
Founded
2001
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.9B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
IHS
IDYA
Price
$8.21
$32.13
Analyst Decision
Buy
Strong Buy
Analyst Count
7
16
Target Price
$8.11
$51.21
AVG Volume (30 Days)
2.3M
801.6K
Earning Date
03-16-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.90
EPS
N/A
N/A
Revenue
N/A
$218,710,000.00
Revenue This Year
$3.90
N/A
Revenue Next Year
$2.64
$191.08
P/E Ratio
$5.85
N/A
Revenue Growth
N/A
3024.43
52 Week Low
$4.21
$13.45
52 Week High
$8.95
$39.28

Technical Indicators

Market Signals
Indicator
IHS
IDYA
Relative Strength Index (RSI) 54.47 46.19
Support Level $7.82 $29.15
Resistance Level $8.21 $33.64
Average True Range (ATR) 0.10 1.40
MACD 0.00 -0.24
Stochastic Oscillator 60.00 43.37

Price Performance

Historical Comparison
IHS
IDYA

About IHS IHS Holding Limited

IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: